-

Karen L. Ling joins Galderma’s Advisory Committee

ZUG, Switzerland--(BUSINESS WIRE)--Galderma, the world’s largest independent dermatology company, announced today that Karen L. Ling will join its Advisory Committee, effective March 1, 2022.

Karen Ling has a tremendous track record in executive roles at AIG, Allergan, Merck and Wyeth, guiding compensation, culture and program strategies that greatly improved shareholder relations and attracted and retained competitive talent. She is an accomplished global human resources executive with more than 25 years of pharmaceutical industry experience.

Ms. Ling recently retired from her role as Executive Vice President and Chief Human Resources Officer of American International Group, Inc. (AIG). In this role, she oversaw all aspects of human capital management, including talent development, talent acquisition, compensation and benefits, and diversity, equity and inclusion. At Allergan, as Executive Vice President and Chief Human Resources Officer, she unified multiple, successive acquisitions. She was also instrumental in various innovative compensation programs for the executive leadership team, focused on increasing shareholder value.

 

“I am very pleased to welcome Ms. Ling to Galderma. She
brings to Galderma’s Advisory Committee her extensive
expertise in the area of human resources management, having
led the human capital function at major multinational
companies. She also has wide experience in mergers and
acquisitions – leading seamless integrations and unifying
multiple acquisitions under a shared mission and brand.”

 

THOMAS EBELING

CHAIRMAN ADVISORY COMMITTEE, GALDERMA

 

Ms. Ling currently sits on the Board of Directors and Compensation Committee of iRhythm Technologies (NASDAQ: IRTC) and also sits on the Board of Directors and is Chair of the Compensation Committee of TherapeuticsMD (NASDAQ: TXMD). In addition, she sits on the Board of two non-profit organizations, ExpandED and the JED Foundation. Ms. Ling holds a Juris Doctor from the Boston University School of Law and earned her undergraduate degree from Yale University.

 

“We are thrilled that Karen Ling has decided to join us. Karen has
been a strategic advisor to several Boards of Directors and has
been a member of the executive leadership teams of a number of
global corporations. Karen also has great experience in building
strong performance-based and inclusive organizational cultures.
This appointment will certainly strengthen our Advisory
Committee and also shows our commitment to diversity at
Galderma.”

 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER, GALDERMA

 

About Galderma
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Contacts

Media contact

Christian Marcoux
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Galderma


Release Versions

Contacts

Media contact

Christian Marcoux
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Social Media Profiles
More News From Galderma

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based regenerative skincare. As a pioneer in peri‑procedural skincare, Alastin helped establish the category with the original Regenerating Skin Nectar — one of the first products specifically developed to prepare the skin before cosmetic procedures, complement procedural...

Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra – the first proven regenerative biostimulator – and the company’s versatile hyaluronic acid injectable Restylane range, in addressing the aesthetic changes associated with menopause and medication-driven weight loss, for the face and body.1-7 Data includes an analysis from a first-of-its-kind study evaluating optimal treat...

Galderma Debuts ALASTIN Signature Practices in Partnership With Leading Aesthetic Practices to Elevate Regenerative, Peri-Procedural Skincare

MIAMI--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of ALASTIN Signature Practices, a new designation for dermatology, plastic surgery, and medical aesthetics practices that integrate ALASTIN’s comprehensive regenerative skincare portfolio into treatment planning and patient care. Colorado Springs Dermatology Clinic is the first ALASTIN Signature Practice, with additional Signature Practices planned across the United States in 2026...
Back to Newsroom